Analysts Offer Predictions for ABEO Q1 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Abeona Therapeutics in a research report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will post earnings per share of ($0.10) for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Other equities research analysts also recently issued research reports about the stock. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 target price on the stock. StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.50.

Abeona Therapeutics Trading Down 1.4 %

ABEO traded down $0.07 during trading on Tuesday, reaching $4.97. The company had a trading volume of 529,297 shares, compared to its average volume of 408,282. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The business has a 50 day simple moving average of $5.42 and a 200-day simple moving average of $5.81. The stock has a market cap of $241.21 million, a P/E ratio of -1.85 and a beta of 1.79. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $8.45.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19.

Institutional Trading of Abeona Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Twinbeech Capital LP bought a new position in shares of Abeona Therapeutics in the fourth quarter worth about $58,000. Northern Trust Corp boosted its position in Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 11,478 shares during the period. Squarepoint Ops LLC purchased a new stake in Abeona Therapeutics in the 4th quarter valued at about $67,000. Jane Street Group LLC bought a new position in Abeona Therapeutics in the 3rd quarter worth about $84,000. Finally, Oxford Asset Management LLP purchased a new position in shares of Abeona Therapeutics during the fourth quarter worth approximately $118,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.